Tag Archives: Gena Wang

Barclays Thinks Precision BioSciences’ Stock is Going to Recover

In a report issued on August 13, Gena Wang from Barclays maintained a Buy rating on Precision BioSciences (DTIL – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $6.16, close to its 52-week

Barclays Remains a Hold on Retrophin (RTRX)

Barclays analyst Gena Wang maintained a Hold rating on Retrophin (RTRX – Research Report) yesterday and set a price target of $21.00. The company’s shares closed last Friday at $19.84, close to its 52-week high of $21.92. According to TipRanks.com,

Analysts Conflicted on These Healthcare Names: Bluebird Bio (NASDAQ: BLUE), Phibro Animal Health (NASDAQ: PAHC) and Gossamer Bio (NASDAQ: GOSS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bluebird Bio (BLUE – Research Report), Phibro Animal Health (PAHC – Research Report) and Gossamer Bio (GOSS – Research Report). Bluebird Bio (BLUE) In a

Analysts Offer Insights on Healthcare Companies: Seattle Genetics (NASDAQ: SGEN) and Amgen (NASDAQ: AMGN)

Analysts fell to the sidelines weighing in on Seattle Genetics (SGEN – Research Report) and Amgen (AMGN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Seattle Genetics (SGEN) Barclays analyst

Vir Biotechnology (VIR) Gets a Buy Rating from Barclays

Barclays analyst Gena Wang maintained a Buy rating on Vir Biotechnology (VIR – Research Report) on March 27 and set a price target of $41.00. The company’s shares closed last Friday at $34.30. According to TipRanks.com, Wang is a 5-star

PTC Therapeutics (PTCT) Receives a Hold from Barclays

Barclays analyst Gena Wang maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of $51.00. The company’s shares closed last Monday at $51.87. According to TipRanks.com, Wang is a 5-star analyst with